Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.44 |
| ▸ | CDK1 | P06493 | 5/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633620 | 1.00 | RET (0.45) | RETCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29049063 | 1.00 | RET (0.45) | RETCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21811780 | 0.84 | RET (0.50) | RETCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21909261 | 0.83 | ERN1 (0.46) | RETMAPK8MAPK9MAPK10 | |
| SCHEMBL28554822 | 0.83 | ERN1 (0.46) | RETMAPK8MAPK9MAPK10 | |
| SCHEMBL25071801 | 0.83 | ERN1 (0.46) | RETMAPK8MAPK9MAPK10 | |
| SCHEMBL31145241 | 0.82 | MAPK10 (0.45) | RETCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL24435876 | 0.82 | TEK (0.42) | MAPK8MAPK9MAPK10AURKB | |
| SCHEMBL29633613 | 0.82 | TEK (0.42) | MAPK8MAPK9MAPK10AURKB | |
| SCHEMBL16091554 | 0.81 | KDM1A (0.50) | JAK3JAK2TYK2MAPK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583276-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-08-11 | — | — | CN | disclosed |
| US-20220153723-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | UNIVERSITY OF WASHINGTON | 2022-05-19 | — | — | US | disclosed |
| WO-2022104151-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153723-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | XBP1, ERN2, ERN1 | RET 3620/4885CCNB2 4632/4885CDK1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.